Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues
Abstract Clinical use of polygenic risk scores (PRS) will look very different to the more familiar monogenic testing. Here we argue that despite these differences, most of the ethical, legal, and social issues (ELSI) raised in the monogenic setting, such as the relevance of results to family members...
Main Authors: | Anna C. F. Lewis, Robert C. Green |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Genome Medicine |
Online Access: | https://doi.org/10.1186/s13073-021-00829-7 |
Similar Items
-
Polygenic risk scores in the clinic: Translating risk into action
by: Anna C.F. Lewis, et al.
Published: (2021-10-01) -
Potential use of clinical polygenic risk scores in psychiatry – ethical implications and communicating high polygenic risk
by: A. C. Palk, et al.
Published: (2019-02-01) -
Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
by: Anna C. F. Lewis, et al.
Published: (2022-10-01) -
Polygenic risk scores: from research tools to clinical instruments
by: Cathryn M. Lewis, et al.
Published: (2020-05-01) -
Polygene Risk Scores
by: James Woodward, et al.
Published: (2023-07-01)